From the Leader's Desk |
After the price reduction of 10 drugs under the Inflation Reduction Act last year, the next batch of 15 drugs subject to Medicare price negotiations was announced on Jan 17. Industry watchers believe President Donald Trump will likely continue the outgoing Biden administration’s policy of lowering the prices of popular drugs for senior citizens. In response, biopharma leaders are rethinking their R&D strategy by adopting stricter pipeline management and enacting cost-reduction measures, including program prioritization, staff reductions, site consolidation, and augmented externalization. Partnering with an experienced CRO-CDMO like Syngene could help build greater efficiencies early-on, reducing overall cost per program without sacrificing timelines or probability of success. Separately, we are delighted to announce that we recently won three 2024 Pharmaceutical Technology Excellence Awards: Innovation, Business Expansion, and Environmental Sustainability. We also won multiple awards for showcasing continuous improvement at the National Convention of Quality Concepts (NCQC) 2024 (India), one of the largest quality events in the world.
Happy reading. |
|
|
Kenneth J. Barr, Ph.D.Senior VP, Research ServicesSyngene International Ltd. |
|
|
 |
Interview |
The Future of Therapeutics: Syngene Leading the Charge with Targeted Protein Degradation Platform |
In an exclusive interview with Pharmaceutical Technology, our SVP of Research Services, Kenneth Barr discussed the company's pivotal role in advancing targeted protein degradation (TPD) as a transformative approach to drug discovery. Emphasizing Syngene's expertise in precision targeting and success in oncology and neurodegenerative research, he spoke about how the company is integrating AI-powered platforms with advanced chemistry to drive innovation and accelerate drug discovery. |
| Read more |
|
 |
Webinar |
ADME strategy and challenges: Heterobifunctional degraders |
Syngene successfully launched its DMPK-focused scientific webinar series, 'DMPK Unravelled', on December 4, 2024. The keynote speaker for the webinar was Dr. Prasoon Chaturvedi, VP and Head of DMPK at C4 Therapeutics. Speakers from Syngene, included Dr. Vishwottam Kandikere, Head of DMPK and Amol Raje, Assistant Director, DMPK. The webinar attracted 200+ attendees from 70+ biopharma companies comprising Directors, VPs, and CXOs. |
| Watch now |
|
|
 |
In the Spotlight |
SYNe-MAP: An online solution for hassle free outsourcing of your DMPK assays |
Outsourcing DMPK services is often hindered by a lack of visibility into available assays, lengthy order processing times, and limited updates about the order status. Our newly launched SYNe-MAP platform addresses these challenges by providing a smooth, and intuitive way to order, track, and manage over 450 ADME-PK assays. SYNe-MAP offers real-time tracking, integrated rate cards, and easy-to-use assay options. The platform demonstrates Syngene’s dedication to delivering a seamless, fully digital solution to enhance drug discovery workflows. To explore the platform, click on the button below, and then request access. |
| Explore the platform |
|
 |
Case Study |
IND-enabling safety tox studies for FDA submission in just 9 months
|
A clinical-stage pharmaceutical company partnered with Syngene for IND-enabling safety tox studies for a non-opioid therapeutic, targeting painful neuropathies. Studies included safety pharmacology, genotoxicity, 35-day repeat dose toxicity in two species, analytical validations, and SEND dataset preparation per FDA standards. Our team of expert scientists completed the studies in record time, enabling the client to submit the IND application in just nine months. The pharma company has since received IND clearance from the FDA to initiate clinical trials.
|
| Read case study |
|
|
|
|
SOT Annual Meeting & ToxExpo 2025 |
|
March 16-20, 2025 |
Orlando, FL |
|
|
|
|
